Near-Infrared Laser Adjuvant for Influenza Vaccine
Hibert, Mathew L.
Lee, Eugene L. Q.
MetadataShow full item record
CitationKashiwagi, S., J. Yuan, B. Forbes, M. L. Hibert, E. L. Q. Lee, L. Whicher, C. Goudie, et al. 2013. “Near-Infrared Laser Adjuvant for Influenza Vaccine.” PLoS ONE 8 (12): e82899. doi:10.1371/journal.pone.0082899. http://dx.doi.org/10.1371/journal.pone.0082899.
AbstractSafe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, near-infrared (NIR) laser light given in short exposures to small areas of skin, without the use of additional chemical or biological agents, significantly increases immune responses to intradermal influenza vaccination without augmenting IgE. The NIR laser-adjuvanted vaccine confers increased protection in a murine influenza lethal challenge model as compared to unadjuvanted vaccine. We show that NIR laser treatment induces the expression of specific chemokines in the skin resulting in recruitment and activation of dendritic cells and is safe to use in both mice and humans. The NIR laser adjuvant technology provides a novel, safe, low-cost, simple-to-use, potentially broadly applicable and clinically feasible approach to enhancing vaccine efficacy as an alternative to chemical and biological adjuvants.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879353
- HMS Scholarly Articles